Denver-based CereHealth Corp., a provider of biotechnology applications and advanced neurodiagnostics, announces that its FDA-cleared population template, an alternative to normative datasets for quantitative analysis of clinical brain SPECT, will be presented by the company’s senior medical imaging engineer, Lindsay Quandt, MS, MBA, at the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI’s) Annual Meeting on July 11-14.
The virtual conference, titled “Diagnosis to Therapy: The Future of Image-Guided Patient Management,” will be attended virtually by more than 2,500 society members and insiders of the nuclear medicine and molecular imaging industry worldwide.
A recorded oral presentation of the collaboration between Quandt and coauthor, Cyrus Raji, MD, PhD, will be featured in the conference’s online Science Pavilion. Quandt will review their analysis of how a large collection of clinical scans can substitute a small dataset of normal subjects for the identification and quantification of perfusion abnormalities in brain SPECT imaging. She will highlight how the population template was generated from more than 2,000 heterogenous clinical scans and validated against a normative dataset of 90 controls.
Based on the high rating that the abstract received from the conference’s review panel, a condensed version of its content is currently under consideration to be featured by Dr. Irene Buvat during her Physics, Instrumentation and Data Sciences (PIDS) Summary Session on Sunday, July 12.
“One of the many benefits in having a large, consistently acquired and continuously expanding clinical dataset is that it allowed us to explore an alternative method for SPECT quantification that was counterintuitive but ultimately consistent with the current gold standard,” says Shane Quint, CTO of CereHealth Corp. “Through the verification and validation process for the FDA, it became evident that our approach made sense and could be applied clinically. SNMMI’s invitation to present to the keenest minds applying these methods in daily practice is an exciting opportunity.”
CereHealth’s FDA 510(k)-cleared CereMetrix platform delivers radiologists and treating providers with advanced neuroimaging analysis tools in a web-enabled environment. Strong 3D visualizations and voxel-level perfusion measurement enable consistent and detailed assessments of patients’ brain health. CereMetrix’s viewer, paired with its clinical data collection and automated reporting, equip physicians with the tools necessary to deliver comprehensive neurodiagnostic evaluations.
“The level of accuracy encompassed in CereMetrix’s population template provides a clear pathway to identify abnormalities, which in turn allows me to explain the connection to my patient’s symptoms,” says Shaun O’Leary, MD, PhD, a Chicago neurosurgeon who has been using CereMetrix’s reporting since 2018. “I can tell my patients that abnormalities identified in their quantitative brain imaging have been vetted through a method that is as good as the present gold standard AND will continue to get better as more patients are included.”